Skip to main content
Loading

Inimmune Inc.

October 15, 2024
Hunt Room
Oncology
Inimmune Inc.
Inimmune designs and develops novel immunotherapeutic compounds and delivery systems that target relevant pathways of the innate immune system to drive disease-modifying responses in areas of high unmet medical need. Our lead clinical programs include a TLR4 agonist, INI-2004, for seasonal allergic rhinitis and a TLR7/8 agonist, INI-4001, for cancer delivered in proprietary liposomal formulations. In addition, Inimmune develops novel vaccine adjuvants and has entered into a worldwide commercialization & distribution agreement with SPI for selected vaccine adjuvants from the Inimmune portfolio.
Speakers
Alan Joslyn - PhD, Chief Executive Officer - Inimmune Inc.

DOUBLE HELIX SPONSOR

HELIX SPONSOR

PREMIER SPONSOR

CONFERENCE SPONSORS